 SOUTH SAN FRANCISCO, Calif., March 22, 2021 GLOBE NEWSWIRE -- Akero Therapeutics, Inc. Nasdaq: AKRO, a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis NASH, today announced that the company plans to discuss new efficacy and safety data, including biopsy results, from an expansion cohort of a 16-week Phase 2a clinical trial, Cohort C, evaluating efruxifermin EFX in the treatment of adult patients with cirrhotic nonalcoholic steatohepatitis NASH in a post-market press release and webcast to be held today, March 22, 2021. 